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There are approximately 2 million people now living with or
beyond cancer in the UK (Maddams et al, 2009) and this number is
increasing. Cancer survivors can experience physical, psychologi-
cal and social consequences as a result of the disease and the
treatments received (Jefford et al, 2008; Foster et al, 2009). The
effects may be immediate, some of which will resolve and others
may persist and become long-term. Late effects can also occur and
the interval between the end of treatment and onset can range from
a few weeks (e.g. lymphoedema after axillary node removal) to
several years (e.g. heart disease following radiotherapy to the chest
area). Problems will be individual to each patient due to a unique
combination of circumstances including the site and stage of the
cancer, the type of treatment(s) given, the age of the patient,
genetic factors, concomitant co-morbidities, family and social
circumstances, and personality traits.
The recent National Cancer Survivorship Initiative (NCSI)
acknowledges the range of issues which cancer survivors may
face, and highlights the need for health professionals to organise
care accordingly (NCSI, 2010a). The recent NCSI Research
Priorities Report (NCSI, 2010b) identified two areas of priority
for research to inform practice: the establishment of large cohort
studies (to determine the range and frequency of problems
following treatment) and the development of risk stratification
tools. However, the report did not develop a detailed definition
of risk stratification nor did it elucidate what outcomes risk
stratification should address.
The purpose of this paper, prepared by members of the
Survivorship Sub-group of the National Cancer Research Institute
Primary Care Clinical Studies Group, is therefore to further define
the term risk stratification in relation to cancer survivorship; to
propose a framework for risk stratification; and to consider what
research is required to support its implementation. The focus of
our paper is on stratifying risk in relation to the late effects of
diagnosis and treatment. We do not therefore address prognostic
risk stratification, a topic for which there is already a large body
of literature.
DEFINITION OF RISK
We have defined risk stratification as the process of quantifying
the probability of a harmful effect to individuals resulting from
a range of internal and external factors (e.g., demographic
characteristics, genetic make-up, medical treatments). Risk must
be differentiated from (healthcare) need, which is the capacity to
benefit from health care. A need must be present at the time of
assessment, unlike a risk, which implies something that might
happen in the future. The assessment of both risk and need are
required in the context of cancer survivorship. The categorisation
of outcomes presented in Box 1, which we believe may warrant risk
stratification following diagnosis and treatment of cancer, could
also apply to needs assessment.
RISK STRATIFICATION IN CANCER SURVIVORS
There are already many examples in medicine of clinical prediction
tools to assess risk and determine clinical management. For example,
Framingham and Q risk scores for cardiovascular risk and the Wells
score for deep vein thrombosis. Some also exist in psychology, for
example, the Social Readjustment Rating Scale (Holmes and Rahe,
1967) gives a risk score for later onset of stress-related illness on the
basis of how many stressor events have been experienced.
The challenge in relation to cancer survivorship is to develop
tools for stratifying individual risk across a range of outcomes
(medical and psychosocial). This includes assessment of:
 which patients are at risk of which adverse outcomes and the
magnitude of the risk;
 the significance of the risk in terms of its’ impact on the
individual;
 the availability of effective interventions;
 the health economic implications of managing the risk.*Correspondence: Professor EK Watson; E-mail: ewatson@brookes.ac.uk
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This information will be useful to the health care system to
specify the follow-up pathway, and to the patient to enable
informed decisions about interventions and life style changes to
reduce risk.
Currently, risk stratification in relation to cancer tends to focus
on risk of recurrence and is used to inform follow-up pathways.
However, there are as yet very few cancers, where there is good
evidence to suggest early identification of recurrence reduces
mortality: there is evidence for more intensive follow up of
colorectal cancer reducing mortality (Renehan et al, 2002), but not
breast cancer (Rojas et al, 2005). There also tends to be insufficient
attention to psychosocial dimensions, which can be very important
to patients and their families.
We propose that risk stratification should be viewed as a
screening test whereby a population at potential risk (all cancer
survivors) are offered a test (risk stratification tool) to determine
those who need further investigation, intervention or support.
Therefore, a modification of the Wilson–Junger criteria (Wilson
and Junger, 1968) for an effective screening test could determine
which cancer outcomes warrant risk stratification (Box 2). As well
as the development of pre-symptomatic interventions, this
approach would require additional knowledge of the timing and
magnitude of these outcomes in a general population of cancer
survivors (as opposed to the population followed up in clinical
trials). This may be particularly problematic for psychosocial co-
morbidities where the prediction of long-term problems is
complex due to the subjective nature of symptoms and the
multifaceted nature of variables, which might affect their onset.
Tables 1a and 1b describe the incidence of various treatment
effects for breast and prostate cancer, respectively. Although there
is some evidence available regarding the incidence of long-term
and late effects, this is not always well described and, importantly,
there are few proven interventions for those at high risk.
In terms of assessment after treatment is complete, long-term
and late effects fall into three categories:
 Those already present and where management will be
determined by needs assessment.
 Those problems that are not necessarily present immediately
after treatment, but where our criteria for risk assessment are
not fulfilled.
 Those that fulfil the modified Wilson and Junger criteria and
will therefore qualify for risk stratification.
The first category would include all long-term effects of treatment,
for example, urinary and sexual problems resulting from the
treatment of prostate cancer. Depression and anxiety may occur at
any time and it might be possible to stratify the risk and timing of
their occurrence. However, validated screening tools are available,
and we suggest a needs assessment approach is most appropriate
in this case. The second and third categories are more problematic.
For example, the relationship between breast cancer treatment and
heart failure is well established (Ewertz and Jensen, 2011) and it is
possible to identify those at greatest risk using echocardiography.
However, incidence is low and there is no evidence yet that pre-
symptomatic treatment affects outcome (Wang et al, 2003) so this
condition does not fulfil our criteria for risk assessment at present.
In the case of osteoporosis following hormone therapy for
treatment of prostate cancer, there is a good screening test
available (bone mineral density screening) and there is an
intervention available to reduce the risk of fractures (bispho-
sphonates), which is an important health problem (Greenspan
et al, 2007). A risk assessment and stratification approach could
therefore be beneficial in this case. However, there are currently
very few late effects that qualify for risk assessment and
stratification using these criteria, and we suggest that for now
most long-term and late effects will be managed by needs
assessment, continuing current practice of managing the problem
as it arises. There is a range of screening tools already available for
assessing physical and psychological needs, for example, Distress
Thermometer, Health Anxiety and Depression Score (HADS) and
International Prostate Symptom Score (IPSS).
PATIENT PERSPECTIVE
One important issue to consider is the extent to which patients
wish to know their risks, especially when there may be few
interventions to minimise these risks before they become an overt
problem. Risk information can sometimes be complex, and we
need to establish the best ways to convey information in a way that
patients can understand and retain (Calman and Royston, 1997).
There is the potential to cause more harm than benefit. For some,
knowledge of future risk may be a significant risk factor for later
anxiety, depression and fear. Some patients will prefer to put their
cancer experience behind them at the end of treatment, and move
on with their lives, and it is important they be allowed to do this
(Khan et al, 2011). Others may wish to know the risks of
recurrence and/or late effects and to take whatever preventive
action or to seek help promptly if any problems occur. Currently it
is not known when the optimal time is or what the optimal
approach is to discuss risks with a patient, and who is best placed
to do this.
Box 2 Modification of the Wilson and Junger (1968) criteria for use in
risk stratification in cancer survivors
1. The condition/problem should be an important health problem.
2. There should be an effective intervention (e.g., prevention, treatment or
supportive mechanism) for the condition/problem (as determined by a
randomised controlled trial or as high a level of evidence as possible).
3. Facilities for diagnosis and treatment should be available.
4. There should be a latent stage between diagnosis/treatment and onset.
5. There should be a test, psychometric measure or examination for
detection of the condition/problem.
6. The test, measure or examination should be acceptable to the population.
7. The natural history of the condition/problem should be adequately
understood.
8. There should be an agreed policy on whom to treat.
9. The total cost of finding a case should be economically balanced in relation
to expenditure as a whole.
10. Assessment should be a continuous process, not just a ‘once and for all’
project.
Box 1 Outcomes following diagnosis and treatment of cancer, which
may warrant risk assessment
K Physical health
J Recurrence
J Long-term effects of treatment
J Late effects of treatment
J Effect on co-morbidities
J Death
K Psychological health
J Increased depression
J Increased anxiety, including fear of recurrence
J Psychosexual problems
J Quality of life
K Social issues
J Financial
J Employment
J Education
J Interpersonal
J Social interaction
J Disability
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A FRAMEWORK FOR RISK STRATIFICATION
AND NEEDS ASSESSMENT FOLLOWING CANCER
TREATMENT
Risks will vary throughout the cancer trajectory and one single
assessment may not be sufficient.
We propose the first time point for risk stratification is
following diagnosis and pre-treatment. At this stage it is possible
to stratify to a degree according to the known side-effect profile of
certain treatments. Psychosocial factors could also influence the
success or compliance with treatment recommendations. The
second time point would be on completion of primary treatment.
Whereas the ideal would be to have a single tool, in reality it is
likely there will be a core tool addressing risks relevant to most
cancers, with site-specific additions required. This would inform
the follow-up strategy and care plan for the patient, and could be
shared with the patient as appropriate. The NCSI is currently
proposing that those patients at low risk of recurrence and late
effects (physical and psychosocial) would be encouraged towards
supported self-management, those at medium risk would have
Table 1a Long-term and late effects following breast cancer treatment (Irwig and Bennetts, 1997; Petrek et al, 2001; Murphy et al, 2007; Ewertz and
Jensen, 2011; NHS Information Centre, 2011)
Long term/late effect Incidence Timing Risk factors
Shoulder/arm pain 47% 1–3 years (13% severe)
20–30% after 3 years
Immediate Young age, axillary dissection,
radiotherapy
Hot flushes 50–70% Immediate Young age hormone blocking treatment
Lymphoedema 15–25% 1–5 years
1% per year 3–20 years
Immediate and resolving, but
some new cases present late
Mastectomy, radiotherapy,
axillary dissection, young age
Arthralgia 35% Immediate to 5 years Tamoxifen
Aromatase inhibitors
Premature menopause 55% o40 years
90% 440 years
Chemotherapy
Osteoporosis 20% 2–5 years Aromatase inhibitors
Cardiovascular disease 0.5–4% following chemotherapy
3% increase in death after
radiotherapy per Gy
Death rate increases from 10 years Chemotherapy, radiotherapy
Wound pain or numbness 10% 2 months–5 years Mastectomy, axilliary gland clearance
Poor cosmesis/reconstruction 20% will have reconstruction
Depression 14 vs 5% In general population Young age, previous psychiatric disease,
low socio-economic status
Sleep disturbance 39%
Fatigue 20–30% at 2 years
5–34% ongoing
Immediate and long term
Table 1b Long-term and late effects following prostate cancer treatment (Shahinian et al, 2005; Ganz, 2009; Smith et al, 2009; Harrison et al, 2011)
Treatment effect Incidence Timing Risk factors
Urinary incontinence 12.3% Following radical prostatectomy at 3 years
2.7% following radiotherapy at 3 years
7% following brachytherapy at 3 years
4.3% following hormone treatment at 3 years
Immediate – can be long term with
problems resolving in some instances
Problems more common following
radical prostatectomy
Bowel problems 3.5% Following radical prostatectomy at 3 years
14.5% following radiation therapy at 3 years
9.3% following brachytherapy at 3 years
6.4% following hormone treatment at 3 years
Sometimes immediate, sometimes delayed,
can be long term with problems resolving
over time in some instances
Problems more common following
radiotherapy
Erectile dysfunction 77.4% following radical prostatectomy at 3 years
67.9% following radiotherapy at 3 years
72.1% following brachytherapy at 3 years
97.8% following hormone therapy at 3years
Immediate, often long term. Treatments
can sometimes be effective and sometimes
the problem will resolve over time
Radical prostatectomy, radiotherapy,
hormone treatment
Risk of fracture 5 years post-diagnosis, 19.4% of men receiving hormone
therapy with fractures compared with 12.6% of those
who had not received hormone therapy.
Delayed effect Hormonal treatment
Anxiety/depression Can occur at any time Trait anxiety
Hot flushes Up to 75% of patients Hormonal treatment
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planned, co-ordinated care and those at high risk would receive
complex care from specialist services. Needs assessment remains
very important during follow-up and should complement risk
stratification efforts. For non-complex cases, current cancer follow
up usually involves 3–5 years of follow up under the care of a
hospital consultant, and we would propose needs (medical and
psychosocial) be monitored and addressed at each follow-up
appointment. Guidelines should be drawn up to ensure all
potential needs are assessed and there is uniformity among
different hospitals. Patients are subsequently discharged from
hospital follow-up to general practitioner care, and we propose this
as the third time point when risk assessment and stratification
would be appropriate. The GP (and patient if appropriate) would
then be informed regarding possible risks, and the appropriate
monitoring, screening and health promotion activities to undertake in
the future. Currently patients have a cancer care review with their GP
within 6 months of diagnosis. Although this often takes place before
the end of active treatment, it does provide an important opportunity
for an initial needs assessment in primary care. Additional cancer
care reviews could become the vehicle for continuing needs assess-
ment at regular (perhaps annual) intervals in the primary care
setting, according to patient preferences (see Figure 1).
WHAT ARE THE PRIORITIES FOR RESEARCH?
Research is needed to establish how common late effects are for
different cancer sites and treatment regimes, which factors (both
physical and psychosocial) are amenable to risk assessment and
stratification, how we elicit and assess these risks, what interven-
tions are effective and, importantly, the level of benefit afforded to
patients as a result. We also need to develop a better under-
standing of patients’ preferences in this area and to develop clear
and effective strategies for communicating the various risks
following treatment to patients and their families. There needs to
be robust evaluation of risk stratification tools that are developed,
including developing an understanding of factors, which influence
compliance with recommended treatments or lifestyle changes.
CONCLUSIONS
Many individuals with cancer can now expect to be cured or to
survive for long periods of time. However, survivors can
experience a range of short and long-term physical and
psychosocial sequelae following treatment, and methods of
maximising recovery are needed. Long-term follow-up needs to
be rationalised, and to be consistent across centres. Risk
stratification, identifying those most likely to have significant
problems in the future and intervening accordingly, is an attractive
notion, which could inform commissioning of cancer services. The
challenge is to individually stratify risk for each potential outcome
in order to determine which patients are at risk of which outcomes,
and the magnitude of the risk (both in its effect on the individual
and the health economic implications). Risk stratification should,
however, only be undertaken for outcomes where there are
effective interventions, and a holistic approach to needs assess-
ment remains important. For some, perhaps many, outcomes
regular needs assessment is currently a more suitable approach
than risk stratification.
Long-term follow up involving both needs and risk assessment,
addressing both medical and psychosocial needs, is an enormous
task and must be underpinned by good research evidence. We
suggest that funding agencies plan a research programme
immediately that will identify those late effects of cancer and its
treatment that are important and amenable to modification to
inform future follow-up regimes.
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